| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.075 | 0.1 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.055 | 0.2 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.057 | 0.3 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.051 | 0.3 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.048 | 0.3 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | 0.045 | 0.4 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.044 | 0.4 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.038 | 0.4 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.03 | 0.6 |